Generate Biomedicines (NASDAQ:GENB) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Generate Biomedicines (NASDAQ:GENB) from a hold rating to a sell rating in a research report report published on Saturday morning.

GENB has been the topic of a number of other reports. Zacks Research upgraded Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. Guggenheim initiated coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They set a “buy” rating and a $30.00 target price on the stock. Piper Sandler started coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They set an “overweight” rating and a $24.00 target price on the stock. The Goldman Sachs Group started coverage on Generate Biomedicines in a report on Tuesday, March 24th. They issued a “buy” rating and a $26.00 price objective for the company. Finally, Cantor Fitzgerald started coverage on Generate Biomedicines in a report on Tuesday, March 24th. They issued an “overweight” rating for the company. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Generate Biomedicines presently has an average rating of “Moderate Buy” and an average target price of $25.00.

Generate Biomedicines Trading Up 0.5%

NASDAQ GENB opened at $13.66 on Friday. Generate Biomedicines has a one year low of $11.00 and a one year high of $15.89. The business’s fifty day simple moving average is $12.62.

Generate Biomedicines (NASDAQ:GENB) last released its earnings results on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.